Dow, Oil Prices Soar After Trump Trade Tweet

Trump confirmed a meeting with Xi at next week's G-20 summit

by Karee Venema

Published on Jun 18, 2019 at 11:55 AM

The U.S. stock market is surging at midday, after President Donald Trump tweeted about "an extended meeting" with Chinese President Xi Jinping at next week's G-20 summit. This only strengthens tailwinds created by stimulus chatter from European Central Bank (ECB) President Mario Draghi, and has the Dow Jones Industrial Average (DJI) set for its highest close since May 3. The easing trade tensions have buyers flocking to oil, as well, with July-dated crude up 4.3% at $54.21 per barrel.

Continue reading for more on today's market, including: 

  • Analyst: This bank stock can rally 32%.
  • The levels we're watching on this leveraged gold mining ETF, courtesy of founder and CEO Bernie Schaeffer.
  • Plus, options bear eyes emerging market ETF; analyst sees major upside for TDS; and one drug stock's worst day ever.

midday market stats june 18

The iShares MSCI Emerging Markets ETF (EEM) is seeing unusual options activity today, with around 130,000 puts and 114,000 calls on the tape so far -- two times what's typically seen. Of interest is a block of 47,803 June 41.50 puts that was possibly bought to open for about $1 million (number of contracts * $0.21 premium paid * 100 shares per contract). At last check, the shares of the emerging markets exchange-traded fund (ETF) were up 2.4% at $41.92, set to close north of their 40-day moving average for just the second time since early May.

eem daily chart june 18

Telephone & Data Systems, Inc. (NYSE:TDS) is near the top of the New York Stock Exchange (NYSE) today, after Morgan Stanley upgraded the telecommunications name to "overweight" from equal weight," and raised its price target to $47.50 from $33 -- a 63% premium to last night's close. TDS stock is up 13.4% at $33.12, eyeing its second close north of its 100-day moving average since before a late-February bear gap.

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) is at the bottom of the Big Board, after the neurological drug company announced plans to raise $300 million in equity through a common stock offering, while Leerink also noted Pfizer's (PFE) acquisition of Array Biopharma (ARRY) likely dashed M&A hopes for BHVN. At midday, Biohaven shares are down 23.8% at $43.69, headed for their worst day ever.


A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


  
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


Research Exposes Shortcut to Stock Market Wins
A simple way to stop picking losers, and start cashing in like Wall Street's elite.
Spotify Stock Shaky as Amazon Eyes Podcasts
Amazon's interest in podcasts puts SPOT in focus
AZO Shifts Higher After Earnings
AutoZone's fiscal third-quarter results beat estimates
One New Company Looks Ready To Clean Up On China’s Lithium Mess
Click to continue to advertiser's site.